Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Lanciano
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Lanciano

Peter Lanciano

Board Member, PeriphaGen

CrunchbaseLinkedIn

Peter Lanciano's Career

PeriphaGen
PeriphaGen

Pittsburgh, PA, US

Board Member· Board
Combinent Biomedical Systems
Combinent Biomedical Systems

Lexington, MA, US

Board Member· Board
Neotropix
Neotropix

Malvern, PA, US

Board Member· Board
Sojournix
Sojournix

Arlington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Lanciano's Career

PeriphaGen
PeriphaGen
Series A$6.5M82012Pittsburgh, PA, US
Board Member· Board

Leadership at PeriphaGen

David KriskyDavid KriskyCo-Founder
James WechuckJames WechuckCo-Founder
Darren WolfeDarren WolfeCo-Founder

Similar to PeriphaGen

NeurogeneNeurogeneNew York, NY, USGenetic Medicinesest. 2018NeurogeneNew York, NY, US · est. 2018

Neurogene Inc., a New York-based pharmaceutical company, specializes in developing genetic medicines for rare neurological diseases.

Public · $183.5M92
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Empyrean NeuroscienceEmpyrean NeuroscienceNew York City, NY, USGenetic Therapiesest. 2019Empyrean NeuroscienceNew York City, NY, US · est. 2019

Empyrean: Revolutionizing healthcare with genetic engineering for severe neurological disorders.

Series A · $22M11
NeuroviaNeuroviaSan Francisco, CA, USDrugs, Therapeuticsest. 2013NeuroviaSan Francisco, CA, US · est. 2013

NeuroVia, Inc.: A US-based biopharmaceutical company developing therapies for neurological diseases.

Public · $14M75
Combinent Biomedical Systems
Combinent Biomedical Systems
Acquired$6.3M02000Lexington, MA, US
Board Member· Board

Leadership at Combinent Biomedical Systems

Bob LangerBob LangerBoard Member
William CrowleyWilliam CrowleyBoard Member

Similar to Combinent Biomedical Systems

Credence MedSystemsCredence MedSystemsMenlo Park, CA, USDrug Deliveryest. 2011Credence MedSystemsMenlo Park, CA, US · est. 2011

Credence MedSystems: Innovating drug delivery while preserving trusted pharmaceutical processes.

Series D · $102.4M13
Control Delivery SystemsControl Delivery SystemsWatertown, MA, USBiotechnologyControl Delivery SystemsWatertown, MA, US

Control Delivery Systems: A leading innovator in the biotechnology industry.

Series C · $34.5M50
FemasysFemasysSuwanee, GA, USMedical Devicesest. 2004FemasysSuwanee, GA, US · est. 2004

Femasys: Innovating women's healthcare through R&D and manufacturing of medical devices.

Public · $70.8M34
Advanced BiomedicsAdvanced BiomedicsBaker, LA, USest. 2017Advanced BiomedicsBaker, LA, US · est. 2017

Advanced Biomedics: A stealth-mode healthcare company pioneering in biomedicine.

Seed · $5.1M30
Neotropix
Neotropix
Acquired$11.4M02003Malvern, PA, US
Board Member· Board

Leadership at Neotropix

Paul HallenbeckPaul HallenbeckFounder
Matt RiekeMatt RiekeBoard Member
Sena BiswasSena BiswasBoard Member
Chris KroegerChris KroegerBoard Member

Similar to Neotropix

DnatrixDnatrixHouston, TX, USOncolytic Virus Therapiesest. 2005DnatrixHouston, TX, US · est. 2005

DNAtriX, a Houston-based biotech firm, develops oncolytic virus platforms to treat malignant glioma.

Series B · $57.1M33
NeoantigenicsNeoantigenicsCharlottesville, VA, USCancer Therapiesest. 2012NeoantigenicsCharlottesville, VA, US · est. 2012

Neoantigenics: Pioneering oncology theranostics for urogenital and solid cancers since 2012.

Seed · $2.5M30
Neonc TechnologiesNeonc TechnologiesLos Angeles, CA, USCancer Treatmentest. 2008Neonc TechnologiesLos Angeles, CA, US · est. 2008

NEONC Technologies: An early-stage biotech firm innovating in cancer treatment through unique delivery of plant-derived agents.

Series A · $10.2M6
Sojournix
Sojournix
Series C$70M302016Arlington, MA, US
Board Member· Board

Leadership at Sojournix

Daniel GrauDaniel GrauFounder
Dr Lesley Russell CooperDr Lesley Russell CooperBoard Member
Aaron I DavisAaron I DavisBoard Member
Dan GrauDan GrauBoard Member

Similar to Sojournix

SOV TherapeuticsSOV TherapeuticsMorrisville, NC, USTherapeutics, Treatmentsest. 2009SOV TherapeuticsMorrisville, NC, US · est. 2009

SOV Therapeutics: A NC-based biotech firm specializing in oral testosterone replacement therapies.

Seed · $425k6
X-Biotix TherapeuticsX-Biotix TherapeuticsWaltham, MA, USAntibioticsest. 2016X-Biotix TherapeuticsWaltham, MA, US · est. 2016

X-Biotix Therapeutics: A biotech firm innovating antibiotic solutions for multi-drug-resistant pathogens.

Series A · $7M9
OpsonixOpsonixCambridge, MA, USPathogen Therapyest. 2014OpsonixCambridge, MA, US · est. 2014

Opsonix develops transformative therapies for bloodstream infections and sepsis treatment.

Pre-Seed · $9.3M7
IpiNovyx BioIpiNovyx BioWest Nyack, NY, USTherapeuticsest. 2021IpiNovyx BioWest Nyack, NY, US · est. 2021

IpiNovyx Bio: Pioneering immunoproteasome therapeutics for autoimmune and inflammatory diseases.

Seed · $10M6

Peter Lanciano's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Peter Lanciano

Michael AvonMichael AvonBoard Member · SquadLockerTom PetroTom PetroBoard Member · UnivestAntoine PapiernikAntoine PapiernikBoard Member · Sofinnova PartnersPeter J LevinePeter J LevineBoard Member · AlluxioJohn GiannuzziJohn GiannuzziBoard Member · Boathouse SportsPeter FitzgeraldPeter FitzgeraldCo-Founder · Triventures